← 返回

结内 T 细胞和 NK 细胞淋巴瘤的分类与诊断评估

英文原题:Classification and diagnostic evaluation of nodal T- and NK-cell lymphomas.

查看英文原题

Classification and diagnostic evaluation of nodal T- and NK-cell lymphomas.

PubMed 2022/10/10(内容时间) Virchows Arch Q2 · IF 3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

淋巴结T细胞和NK细胞淋巴瘤是较常见的T细胞恶性肿瘤,多数亚型临床进展凶险。随着对其生物学和分子特征认识的深入,以及精准治疗方法的发展,持续更新这一组恶性肿瘤的分类和诊断标准变得尤为重要。本文依据2022年成熟淋巴肿瘤国际共识分类(2022 ICC),讨论淋巴结T/NK细胞淋巴瘤的分类。滤泡辅助性T细胞来源的淋巴瘤现归为单一疾病实体——滤泡辅助性T细胞淋巴瘤(TFH淋巴瘤),包括血管免疫母细胞型、滤泡型和非特指型3个亚型,以反映其共同细胞来源及共享的分子和临床特征。间变性大细胞淋巴瘤(ALCL)的分类基本未变;DUSP22重排病例现视为ALK阴性ALCL的一种遗传学亚型。原发性淋巴结EBV阳性T/NK细胞淋巴瘤被新增为暂定疾病实体;此前这些病例归为非特指型外周T细胞淋巴瘤(PTCL,NOS)的变异型。PTCL,NOS仍为排除性诊断;不断积累的分子数据提示其中存在不同亚组,包括PTCL-TBX21、PTCL-GATA3和EBV阴性细胞毒性PTCL。本文还讨论有助于按照2022 ICC诊断淋巴结T/NK细胞淋巴瘤的策略,以及如何与结外肿瘤累及淋巴结相鉴别。

展开英文摘要原文

Nodal T- and NK-cell lymphomas are among the most frequent T-cell malignancies and most subtypes have aggressive clinical behavior. Evolving understanding of the biology and molecular characteristics of these lymphomas, as well as the development of new precision therapy approaches, underscores the importance of ongoing updates to the classification and diagnostic evaluation of this group of malignancies.

Here, we discuss the classification of nodal T- and NK-cell lymphomas based on the 2022 International Consensus Classification of Mature Lymphoid Neoplasms (2022 ICC). Lymphomas of T-follicular helper cell origin are now grouped into a single entity, follicular helper T-cell lymphoma (TFH lymphoma), with three subtypes (angioimmunoblastic-type, follicular-type, and not otherwise specified), reflecting their common cellular origin and shared molecular and clinical characteristics.

Classification of anaplastic large cell lymphoma (ALCL) remains essentially unchanged; DUSP22-rearranged cases are now considered a genetic subtype of ALK-negative ALCL. Primary nodal EBV-positive T-/NK-cell lymphoma is introduced as a new provisional entity; these cases were previously considered a variant of peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS).

PTCL, NOS remains a diagnosis of exclusion, with evolving molecular data indicating the presence of distinct subgroups, including PTCL-TBX21, PTCL-GATA3, and EBV-negative cytotoxic PTCLs.

We also discuss diagnostic strategies to facilitate the 2022 ICC classification among nodal T- and NK-cell lymphomas and the distinction from nodal involvement by extranodal neoplasms.

论文信息

作者
Feldman AL、Laurent C、Narbaitz M、Nakamura S、Chan WC、de Leval L、Gaulard P
单位
Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. feldman.andrew@mayo.edu.United States
文献类型
综述
期刊
Virchows Archiv : an international journal of pathology2023 Jan
原文标识
PubMed 36210383 · DOI 10.1007/s00428-022-03412-6

READING GUIDES

相关资料阅读指南

了解这条资料涉及的技术、疾病或试验登记信息,再回到原始来源核实。